CJC-1295

Growth Hormone / Body Composition 🟡 Compounding-Legal
Category
GHRH Analog
Route
Subcutaneous
Frequency
2-3x weekly
Status
Compounding

Overview

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that enhances the production and release of growth hormone from the pituitary gland. As a long-acting GHRH analog, it provides sustained elevation of growth hormone levels, making it highly effective for body composition improvement, anti-aging, and recovery enhancement.

Available in two forms - with and without Drug Affinity Complex (DAC) - CJC-1295 has become one of the most popular peptides for growth hormone optimization. The DAC version provides extended half-life, while the non-DAC version (often called Mod GRF 1-29) offers more natural pulsatile release patterns.

CJC-1295 is frequently combined with Ipamorelin to create a powerful complementary effect, with CJC-1295 amplifying growth hormone pulses and Ipamorelin increasing their frequency.

How It Works

combined effect with Ipamorelin: The combination of CJC-1295 (amplitude) + Ipamorelin (frequency) creates optimal growth hormone optimization.

Benefits

Potential Risks & Side Effects

Common Side Effects

  • Injection site reactions
  • Water retention
  • Joint stiffness
  • Carpal tunnel symptoms

DAC vs Non-DAC Considerations

  • DAC version: Longer half-life but less natural pulsing
  • Non-DAC: More natural patterns but requires more frequent dosing

Typical Protocol

CJC-1295 with DAC

  • Dose: 1-2 mg twice weekly
  • Timing: Morning and evening

CJC-1295 without DAC (Mod GRF 1-29)

  • Dose: 100-300 mcg 2-3 times daily
  • Stack: Often combined with Ipamorelin
🔒

Unlock the full CJC-1295 guide

Get detailed protocols, dosing guides, risk profiles, and research citations.

$9.99/month - Everything included